|
<!-- Clinical data -->|pregnancy_AU=D|pregnancy_US=X|routes_of_administration=[[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])|Drugs.com={{drugs.com|monograph|rosuvastatin-calcium}}|MedlinePlus=a603033|licence_EU=<!-- EMA uses INN (or special INN_EMA) -->|DailyMedID=Rosuvastatin|licence_US=<!-- FDA may use generic or brand name (generic name preferred) -->|pregnancy_category=|dependency_liability=|legal_AU=S4|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=POM|legal_US=Rx-only|legal_status=Rx-only
<!-- Pharmacokinetic data -->|bioavailability=20%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018 />|protein_bound=88%<ref name=PK /><ref name=AHFS2018 />|metabolism=[[Liver]]: [[CYP2C9]] (major) and [[CYP2C19]]-mediated; ~10% metabolized<ref name=PK /><ref name=AHFS2018 />|elimination_half-life=19 hours<ref name=PK /><ref name=AHFS2018 />|excretion=[[Feces]] (90%)<ref name=PK /><ref name=AHFS2018 />
<!-- Pharmacokinetic data -->|bioavailability=20%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|protein_bound=88%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|metabolism=[[Liver]]: [[CYP2C9]] (major) and [[CYP2C19]]-mediated; ~10% metabolized<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|elimination_half-life=19 hours<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|excretion=[[Feces]] (90%)<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
<!-- Chemical and physical data -->|chemical_formula=|C=22|H=28|F=1|N=3|O=6|S=1|molecular_weight=481.539|smiles=OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc2|StdInChI_Ref={{stdinchicite|changed|chemspider}}|StdInChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1|StdInChI_comment=|StdInChIKey_Ref={{stdinchicite|changed|chemspider}}|StdInChIKey=BPRHUIZQVSMCRT-VEUZHWNKSA-N|density=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}
'''Rosuvastatin''', adalah obat golongan [[statin]], digunakan untuk mencegah [[penyakit kardiovaskular]] pada individu yang memiliki risiko tinggi dan mengatasi [[Dislipidemia|lipid abnormal]] . <ref name="AHFS2018">{{Citecite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}</ref> Pada penggunaan obat ini direkomendasikan bersama dengan perubahan pola makan, berolahraga, dan menurunkan berat badan. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Penggunaan obat ini diberikan secara oral. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
Kejadian efek samping obat yang umum terjadi seperti sakit perut, mual, sakit kepala, dan [[Mialgia|nyeri otot]] . <ref name="AHFS2018">{{Cite web|title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/rosuvastatin-calcium.html "Rosuvastatin Calcium Monograph for Professionals"]. ''Drugs.com''. [[American Society of Health-System Pharmacists]] (AHFS). [https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html Archived] from the original on 24 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> Efek samping yang serius pada penggunaan obat ini yakni [[Rabdomiolisis|rhabdomyolysis]], gangguan hepar, dan [[Diabetes melitus|diabetes]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Obat ini tidak direkomendasikan pada ibu hamil karena, membahayakan janin. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Seperti golongan statin lainnya, rosuvastatin mekanisme kerjanya dengan menghambat HMG-CoA reduktase, [[enzim]] yang terdapat di [[hati]] yang berperan dalam memproduksi [[kolesterol]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
Obat rosuvastatin pertama kali dipatenkan pada tahun 1991, dan disetujui untuk medis di Amerika Serikat pada tahun 2003. <ref name="AHFS2018">{{Cite web|title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/rosuvastatin-calcium.html "Rosuvastatin Calcium Monograph for Professionals"]. ''Drugs.com''. [[American Society of Health-System Pharmacists]] (AHFS). [https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html Archived] from the original on 24 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> <ref name="Fis2006">{{Cite book|last=Fischer|first=Janos|last2=Ganellin|first2=C. Robin|date=2006|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|title=Analogue-based Drug Discovery|publisher=John Wiley & Sons|isbn=9783527607495|page=473|access-date=24 December 2018|archive-url=https://web.archive.org/web/20181224220126/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|archive-date=24 December 2018|url-status=live}}</ref> Obat ini juga tersedia dalam [[obat generik]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
== Referensi ==
|
